Maiti Rituparna, Mishra Biswa Ranjan, Jowhar Jaseem, Mohapatra Debadatta, Parida Sansita, Bisoi Debasis
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Clin Psychopharmacol Neurosci. 2017 May 31;15(2):170-176. doi: 10.9758/cpn.2017.15.2.170.
In bipolar disorder, serum brain-derived neurotrophic factor (BDNF) level decreases leading to dysfunctions of critical neurotrophic, cellular plasticity and neuroprotective processes. The present study was conducted to evaluate the change in serum BDNF level with oxcarbazepine monotherapy in bipolar mania.
The present study is a prospective, interventional, open label clinical study conducted on 25 patients of bipolar mania and 25 healthy controls. Detailed history, clinical evaluation including Young Mania Rating Scale (YMRS) scoring and serum BDNF were assessed at baseline for all 50 subjects. The bipolar patients were prescribed tablet oxcarbazepine and followed up after 4 weeks for clinical evaluation and re-estimation of serum BDNF and YMRS scoring.
The serum BDNF level in bipolar manic patients were compared with healthy controls at baseline and results revealed that there is a significant reduction (=0.002) in serum BDNF level in bipolar patients. At follow-up after 4 weeks, the mean change in serum BDNF in bipolar group who were on oxcarbazepine monotherapy was found statistically significant (=0.02) in comparison to healthy controls. In bipolar group, the YMRS score and serum BDNF at baseline have an inverse relation(r=-0.59) whereas change of the YMRS score had a positive correlation (r=0.67) with the change of serum BDNF over 4 weeks.
In bipolar mania serum BDNF level is low and it is found to be increased with short term monotherapy with oxcarbazepine.
在双相情感障碍中，血清脑源性神经营养因子（BDNF）水平降低会导致关键的神经营养、细胞可塑性和神经保护过程功能障碍。本研究旨在评估奥卡西平单药治疗双相躁狂症时血清BDNF水平的变化。
本研究是一项前瞻性、干预性、开放标签的临床研究，对25例双相躁狂症患者和25例健康对照者进行。对所有50名受试者在基线时评估详细病史、包括青年躁狂评定量表（YMRS）评分的临床评估以及血清BDNF。给双相情感障碍患者开奥卡西平片，4周后进行随访，以进行临床评估并重新评估血清BDNF和YMRS评分。
将双相躁狂症患者的血清BDNF水平与基线时的健康对照者进行比较，结果显示双相情感障碍患者的血清BDNF水平显著降低（P=0.002）。在4周后的随访中，发现接受奥卡西平单药治疗的双相情感障碍组血清BDNF的平均变化与健康对照者相比有统计学意义（P=0.02）。在双相情感障碍组中，基线时YMRS评分与血清BDNF呈负相关（r=-0.59），而YMRS评分的变化与4周内血清BDNF的变化呈正相关（r=0.67）。
双相躁狂症患者血清BDNF水平较低，且发现短期奥卡西平单药治疗可使其升高。
